Company: IMCR
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001671927-25-000018
Chunk: 53

Company: Immunocore Holdings plc
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 53
---
 share options8,014— — — 198 — — 198 Share-based compensation expense—— — — 6,509 — — 6,509 As of September 30, 202450,025,620$135 5,793,501$1 $1,180,854 $(771,990)$(31,173)$377,827 

The accompanying notes form an integral part of these condensed consolidated financial statements.

5

Immunocore Holdings plc

Condensed Consolidated Statements of Cash Flows

(Unaudited) (In thousands)

Nine Months Ended September 30,20252024Cash flows from operating activities Net loss$(5,454)$(27,316)Adjustments for:Share-based compensation expense29,359 25,523 Depreciation2,432 3,038 Unrealized foreign exchange gains, net(10,229)(3,982)Unrealized gains on marketable securities(15,224)(13,515)Non-cash lease expense1,681 1,352 Other1,576 1,535 Changes in assets and liabilities:Increase in accounts receivable(9,330)(11,053)Increase in prepayments and other current assets(5,724)(5,910)(Decrease) increase in accounts payable(3,874)1,388 Increase in accrued expenses37,920 72,728 Decrease in deferred revenue(243)(1)Increase (decrease) in operating lease liabilities524 (1,208)Increase in other operating assets(1,471)(4,515)Increase in other operating liabilities— 1,948 Net cash provided by operating activities21,943 40,012 Cash flows from investing activitiesPurchase of marketable securities(30,000)(350,000)Proceeds from sale of marketable securities16,000 — Purchase of property and equipment(1,460)(1,589)Net cash used in investing activities(15,460)(351,589)Cash flows from financing activitiesProceeds from exercise of share options8,087 6,250 Proceeds from issue of convertible senior notes— 402,500 Payments for debt issuance costs— (13,358)Net cash provided by financing activities8,087 395,392 Increase in cash and cash equivalents14,570 83,815 Net foreign exchange difference on cash held28